I think if ORE comes up with numbers then one of the two things will happen - No impact to the underlying EBITDA, the SP should rise - Impact to the underlying EBITDA - the SP will tank heavily.
PTX This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution